Can Mirtazapine Cause Acute Hyperglycemia?
Yes, mirtazapine can cause acute hyperglycemia, though this is an uncommon adverse effect that requires monitoring, particularly in patients with diabetes or metabolic risk factors.
Evidence from FDA Drug Labeling
The FDA-approved labeling for mirtazapine explicitly lists elevated cholesterol and triglycerides as a known adverse effect, with nonfasting triglyceride increases to ≥500 mg/dL observed in 6% of patients treated with mirtazapine compared to 3% for placebo 1. While the FDA label does not specifically list hyperglycemia as a primary warning, the documented metabolic effects (weight gain, increased appetite, and lipid abnormalities) create a metabolic milieu that can precipitate glucose dysregulation 1.
Clinical Case Evidence
Published case reports demonstrate that mirtazapine can trigger acute hyperglycemic crises:
A 44-year-old woman developed severe hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis approximately 2 months after starting mirtazapine 2. All metabolic abnormalities resolved with supportive care and mirtazapine discontinuation, with normal glucose and lipid levels returning within 2 months 2.
A 75-year-old male developed hypertriglyceridemia followed by hyperglycemia resembling diabetes mellitus that required insulin therapy while on mirtazapine for mood and appetite stimulation 3.
A systematic review of 17 published case reports found that hyperglycemia occurred with multiple antidepressants including mirtazapine, with 68% of glucose dysregulation cases occurring within the first month of therapy 4.
Mechanism and Time Course
The glucose dysregulation associated with mirtazapine appears to be mediated through:
- Severe hypertriglyceridemia that can precipitate acute pancreatitis and subsequent diabetic ketoacidosis 2
- Weight gain and increased appetite (reported in 17% vs 2% placebo, with ≥7% body weight gain in 7.5% of patients) 1, which worsens insulin resistance
- Time to onset ranges from 4 days to 5 months, with most cases occurring within the first month of therapy 4
Clinical Monitoring Recommendations
Based on the FDA labeling and case report evidence:
- Measure baseline fasting glucose and triglyceride levels before initiating mirtazapine 2
- Monitor glucose and lipid levels regularly during the first 1-3 months of therapy, when risk is highest 2, 4
- Exercise particular caution in patients with pre-existing diabetes, metabolic syndrome, or obesity 3
- Consider alternative antidepressants in patients with poorly controlled diabetes or severe hypertriglyceridemia 2
Context from Diabetes Guidelines
While diabetes management guidelines do not specifically address mirtazapine-induced hyperglycemia, they do acknowledge that second-generation antipsychotic medications increase diabetes risk and require screening at baseline, 12-16 weeks after initiation, and annually thereafter 5. A similar monitoring approach is prudent for mirtazapine given the documented metabolic risks.
Important Caveats
- The absolute risk of acute hyperglycemia with mirtazapine appears low, but the consequences can be severe (diabetic ketoacidosis, acute pancreatitis) 2
- Mirtazapine is considered safe in cardiovascular disease and has been studied in heart failure populations 6, 7, but metabolic monitoring remains essential
- Discontinuation of mirtazapine typically results in resolution of metabolic abnormalities 2, 3, though triglyceride elevations may persist in some cases 3